Trial Profile
Phase Ib trial of Atu027 in Combination With Cisplatin, 5FU and Cetuximab in Patients With Head and Neck Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 02 Jul 2015
Price :
$35
*
At a glance
- Drugs ATU 027 (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- Acronyms PACiFiC
- 02 Jun 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per United Kingdom Clinical Research Network.
- 15 Sep 2014 New trial record